PDX Model Cohort
Melanoma PDX Models
Advance your Melanoma drug development research using an extensive bank of meticulously curated Melanoma PDX models directly established from primary patient tumors.
Summary
Champions Oncology has established a large cohort of patient Melanoma PDX models, with 47* models available to scientists for melanoma research and drug development. These models are derived from patients with late-stage, metastatic, and heavily pretreated patients while retaining critical molecular features and alterations, making them therapeutically relevant.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading Melanoma PDX Models cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history.
Access to one of the largest bank of Melanoma PDX models with clinically relevant molecularand pathological characteristics on the market.
Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.
Includes models pretreated with advanced therapies like Vemurafenib, Carboplatin, Ipilimumab, and more.
Clinically Relevant Models
Living & diverse bank of clinically relevant models that correlate with clinical outcomes
Ships within 24 hours